MannKind Corporation

NasdaqGM:MNKD Stock Report

Market Cap: US$1.2b

MannKind Future Growth

Future criteria checks 3/6

MannKind is forecast to grow earnings and revenue by 74.1% and 10.1% per annum respectively while EPS is expected to grow by 74.6% per annum.

Key information

74.1%

Earnings growth rate

74.59%

EPS growth rate

Biotechs earnings growth29.0%
Revenue growth rate10.1%
Future return on equityn/a
Analyst coverage

Good

Last updated10 Sep 2026

Recent future growth updates

Analysis Article • May 11

Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

Shareholders might have noticed that MannKind Corporation ( NASDAQ:MNKD ) filed its first-quarter result this time last...
Analysis Article • Mar 01

MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next

MannKind Corporation ( NASDAQ:MNKD ) shareholders are probably feeling a little disappointed, since its shares fell...

Recent updates

Narrative Update • Aug 17

MNKD: Upcoming Autoinjector Decision Will Reframe Perceived Royalty Risk

Analysts have raised their fair value estimate for MannKind from $11.00 to approximately $12.74, citing a higher Street price target of $14 that is tied to Furoscix and MNKD-201 expectations, as well as increased attention on the upcoming Furoscix ReadyFlow Autoinjector FDA decision. Analyst Commentary Recent commentary from bullish analysts on MannKind centers on rising confidence in the Furoscix franchise and the MNKD-201 program.
Seeking Alpha • Aug 13

MannKind: New Approvals Majorly Increase MannKind's Prospects

Summary Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years. While I rate MNKD a " Strong Buy" based upon its FDA approvals, it still has significant risks of execution. Read the full article on Seeking Alpha
Narrative Update • Aug 03

MNKD: Furoscix Autoinjector Approval Will Reset Perceived Royalty Risk

Analysts have lifted their price target on MannKind to $14 from $11, citing higher expectations for Furoscix and the '201 program, along with updated assumptions around tissue exposure and potential Phase 2 read-throughs. Analyst Commentary Recent research coverage around MannKind highlights growing confidence in the company’s pipeline and product execution, particularly around Furoscix and the '201 program.
Narrative Update • Jun 22

MNKD: Pediatric Insulin Approval Will Test Commercial Execution And Reprice Future Upside

The latest narrative update on MannKind reflects a higher analyst price target, moving from $7.17 to $7.59, as analysts highlight Afrezza's pediatric approval while still viewing the company as a "show me" story on commercial execution. Analyst Commentary Recent research on MannKind centers on how Afrezza's pediatric approval could affect the company's long term commercial story, while mixed target moves show differing views on execution risk and valuation.
Narrative Update • Jun 05

MNKD: Pediatric Approval And Trial Progress Will Reset Perceived Royalty Risk

Analysts have raised their MannKind price target to $11 from $8. This reflects updated assumptions that include Afrezza's pediatric approval, a lower discount rate, and higher expected profit margins, even as projected revenue growth and future P/E move slightly lower.
Narrative Update • May 21

MNKD: 2026 Pediatric Decision Will Shape Royalty Overhang And Rebound Potential

Analysts have updated their view on MannKind with a new fair value estimate of $4.75 per share, reflecting recent shifts in price targets as they balance concerns about Tyvaso DPI royalty risk against ongoing contributions from products like Furoscix and Afrezza. Analyst Commentary Recent research highlights a split in how professionals are valuing MannKind, with much of the debate centered on the durability of Tyvaso DPI royalties and how that uncertainty should be reflected in the share price.
Narrative Update • May 04

MNKD: Soft Mist Inhaler Risk Seen Resetting Future Royalty Upside

Narrative Update Analysts have trimmed their average price target on MannKind to about $8. This reflects updated assumptions for higher revenue growth but lower profit margins and a more moderate future P/E as they weigh potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans.
Narrative Update • Apr 20

MNKD: 2026 Pediatric Insulin Decision Will Reset Treprostinil Royalty Risk

Analysts have trimmed MannKind's average price target by about $0.33, reflecting slightly lower assumptions for fair value and profitability as they factor in potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans, even though some still see opportunity in the broader portfolio. Analyst Commentary Recent research has become more cautious on MannKind, with several firms trimming price targets and one moving to a more neutral rating as they reassess the risk and reward around Tyvaso DPI royalties and the impact of United Therapeutics' soft mist inhaler plans.
Narrative Update • Apr 06

MNKD: 2026 Pediatric Decision Will Define Royalty Overhang And Bullish Setup

Narrative Update: MannKind MannKind's updated analyst price target has been reduced from about $7.50 to roughly $3.85, as analysts factor in softer modeled revenue growth, a higher discount rate, lower assumed future P/E and rising concerns that United Therapeutics' planned soft mist inhaler could weigh on the long term value of Tyvaso DPI royalties. Some still highlight potential support from Afrezza and Furoscix and argue the recent selloff may already reflect a worst case scenario.
Narrative Update • Mar 22

MNKD: 2026 Afrezza FDA Decisions Will Recast Treprostinil Royalty Risk

Analysts have trimmed their average price targets on MannKind by a few dollars into the mid single digit range, reflecting fresh concerns about long term Tyvaso DPI royalties as United Therapeutics pursues a soft mist inhaler, while still recognizing potential support from Furoscix and Afrezza. Analyst Commentary Recent Street commentary on MannKind highlights a split view, with many price targets pulled into a mid single digit to low double digit range as analysts weigh Tyvaso DPI royalty risk against potential contributions from Afrezza and Furoscix, as well as MannKind's broader pipeline.
Narrative Update • Mar 08

MNKD: 2026 FDA Decisions On Inhaled Insulin Will Reframe Royalty Risk

Analysts have trimmed their fair value view on MannKind to $7.50 from $9.61, citing lower price targets clustered around $3.50 to $11 as they factor in softer revenue growth and profit margin assumptions, as well as higher perceived risk tied to United Therapeutics' potential soft mist inhaler competition and the timing of Tyvaso DPI royalty data. Analyst Commentary Recent Street research on MannKind reflects a wide split in opinion, with some analysts focusing on potential upside from the broader product portfolio and others emphasizing new competitive risks to Tyvaso DPI royalties and collaboration revenue.
Narrative Update • Feb 22

MNKD: 2026 FDA Label And Pediatric Decisions Will Drive Bullish Case

Analysts have kept their fair value estimate for MannKind steady while refining key inputs like discount rate, revenue growth, profit margin and future P/E. They link their current price targets, including one at $11, to what they see as multiple potential tailwinds tied to upcoming FDA decisions on Afrezza in 2026.
Narrative Update • Feb 07

MNKD: Upcoming FDA Decisions In 2026 Will Define Upside Potential

Narrative Update on MannKind Analysts have trimmed their price target on MannKind from $8.00 to $7.50, balancing reduced fair value and margin assumptions with expectations for stronger revenue growth. They also recognize that recent Street research still highlights potential tailwinds tied to upcoming FDA decisions and the updated pipeline outlook.
Narrative Update • Jan 23

MNKD: 2026 FDA Label Decisions Will Clarify Underappreciated Upside Potential

Narrative Update on MannKind The analyst price target for MannKind has been reset to $10, reflecting updated views after one firm removed MNKD-101/NTM from its valuation while others highlight potential upside tied to upcoming FDA decisions and what they see as underappreciated tailwinds into 2026. Analyst Commentary Recent research on MannKind reflects a mix of optimism around upcoming FDA decisions and caution after the removal of MNKD-101/NTM from valuation models.
Narrative Update • Jan 09

MNKD: 2026 Regulatory Decisions Will Drive Reassessment Of Future Prospects

Narrative Update: MannKind Analyst Price Target Shift Analysts have reset their price targets on MannKind into a tighter US$10 to US$11 range, reflecting a mix of reduced expectations after the discontinuation of MNKD-101/NTM and continued optimism around potential 2026 tailwinds that are not yet fully reflected in the shares. Analyst Commentary Recent research views on MannKind reflect both optimism around potential 2026 catalysts and caution following pipeline changes and trial outcomes.
Narrative Update • Dec 23

MNKD: Future Commercial Execution Will Offset Late Stage Pipeline Disappointment

Analysts have trimmed their price target on MannKind to approximately $10 per share, a modest reduction that reflects the removal of MNKD-101/NTM from valuation assumptions, while improved revenue growth and profit margin forecasts partially offset the impact. Analyst Commentary Analyst reactions to the updated price target highlight a mixed outlook, with optimism around MannKind's core commercial performance tempered by concern over the setback in its development pipeline.
Narrative Update • Dec 09

MNKD: Future Commercial Portfolio Will Offset Pipeline Setback Risk

Analysts have reduced their price target on MannKind from $15.00 to $10.00 per share, citing the removal of MNKD-101/NTM from the pipeline following the discontinuation of the Phase 3 ICoN-1 trial after a futility assessment. Analyst Commentary Analysts view the updated price target as a recalibration of MannKind's valuation to reflect the loss of MNKD-101/NTM from the development pipeline, while still recognizing ongoing strengths in the core business and broader platform.
Narrative Update • Nov 25

MNKD: Recent Pipeline Setback Will Be Outweighed By Future Royalties Expansion

Analysts have reduced their price target for MannKind from approximately $10.06 to $9.39, citing the discontinued Phase 3 ICoN-1 trial and adjusted pipeline expectations as the main factors for the revision. Analyst Commentary Analyst sentiment on MannKind has shifted in response to recent clinical trial results, pipeline updates, and royalty projections.
Narrative Update • Nov 11

MNKD: Acquisition Will Drive Revenue Diversification and Support Upside Re-Rating

MannKind's fair value estimate has been revised down slightly to $10.06 per share from $10.57. Analysts are factoring in stronger revenue growth driven by TYVASO DPI royalties and the accretive acquisition of scPharmaceuticals, along with a modest change in profitability and updated discount rates.
Analysis Article • Sep 03

MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump

MannKind Corporation ( NASDAQ:MNKD ) shareholders would be excited to see that the share price has had a great month...
Narrative Update • Aug 27

Pipeline Advancements And International Expansion Will Shape Future Markets

Analysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings. Analyst Commentary Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.
Analysis Article • May 11

Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

Shareholders might have noticed that MannKind Corporation ( NASDAQ:MNKD ) filed its first-quarter result this time last...
Analysis Article • Mar 01

MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next

MannKind Corporation ( NASDAQ:MNKD ) shareholders are probably feeling a little disappointed, since its shares fell...
Seeking Alpha • Dec 17

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Summary MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, with significant market potential if successfully commercialized. The orphan lung pipeline includes MNKD-101 (Phase 3 for NTM lung disease) and MNKD-201 (Phase 1 for IPF), addressing high unmet needs. Despite high leverage, I believe MNKD's revenue growth prospects support a speculative "Buy" rating for investors seeking exposure to IPF and endocrine biotech niches. Read the full article on Seeking Alpha
Seeking Alpha • Oct 03

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Summary MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases. Financially, MannKind has strong liquidity but remains burdened by long-term debt obligations and modest net losses. I maintain a "buy" recommendation based on MannKind's solid revenue from Tyvaso DPI and its potential in expanding respiratory treatments. Read the full article on Seeking Alpha
Analysis Article • Sep 18

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Despite an already strong run, MannKind Corporation ( NASDAQ:MNKD ) shares have been powering on, with a gain of 28% in...
User avatar
New Narrative • Sep 12

Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability

Strong demand for Tyvaso DPI and advancements in pipeline drugs like clofazimine inhalation suspension highlight MannKind's successful commercial execution and promising revenue growth prospects.
Analysis Article • Jul 17

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

Key Insights The projected fair value for MannKind is US$11.86 based on 2 Stage Free Cash Flow to Equity MannKind is...
Seeking Alpha • May 15

MannKind Outperforms As Tyvaso DPI Captures Market Share

Summary MannKind's Q1 revenue rose 63% year-over-year; net income was $10.63 million, reversing a prior loss. Tyvaso DPI, utilizing MannKind’s technosphere technology, continues to capture significant PAH market interest. Despite high current assets, the Company's long-term liabilities exceed its assets, posing potential financial risks. Recommend buying MNKD for a barbell strategy portfolio, allocating a small portion to this high-alpha stock. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGM:MNKD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20285171022558
12/31/2027504068598
12/31/2026443-5720138
6/30/2026394-44-18-8N/A
3/31/2026361-241319N/A
12/31/202534961418N/A
9/30/2025314294349N/A
6/30/2025302332935N/A
3/31/2025298302229N/A
12/31/2024286283343N/A
9/30/2024267222942N/A
6/30/2024248121841N/A
3/31/20242258340N/A
12/31/2023199-12-834N/A
9/30/2023177-31-3210N/A
6/30/2023158-47-57-27N/A
3/31/2023128-71-72-61N/A
12/31/2022100-87-88-81N/A
9/30/202276-98-98-91N/A
6/30/202266-88-89-78N/A
3/31/202270-94-83-67N/A
12/31/202175-81-73-62N/A
9/30/202181-79-60-49N/A
6/30/202175-86-54-47N/A
3/31/202166-61-35-30N/A
12/31/202065-57-33-28N/A
9/30/202063-45-34-33N/A
6/30/202062-44-73-72N/A
3/31/202062-46N/A-88N/A
12/31/201963-52N/A-88N/A
9/30/201963-47N/A-58N/A
6/30/201953-61N/A-20N/A
3/31/201942-71N/A-28N/A
12/31/201828-87N/A-38N/A
9/30/201816-110N/A-93N/A
6/30/201813-119N/A-102N/A
3/31/201812-131N/A-95N/A
12/31/201711-117N/A-65N/A
9/30/201720-31N/A-48N/A
6/30/2017180129N/A-47N/A
3/31/2017178134N/A-39N/A
12/31/2016175126N/A-78N/A
9/30/2016162-205N/A-88N/A
6/30/2016N/A-364N/A-85N/A
3/31/2016N/A-363N/A-91N/A
12/31/2015N/A-368N/A-57N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MNKD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.7%).

Earnings vs Market: MNKD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MNKD is expected to become profitable in the next 3 years.

Revenue vs Market: MNKD's revenue (10.1% per year) is forecast to grow slower than the US market (13.4% per year).

High Growth Revenue: MNKD's revenue (10.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MNKD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 03:34
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MannKind Corporation is covered by 27 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas RussoBaird
Stephen V. ByrneBofA Global Research
null nullBTIG